Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.LifeScan and ResMed announce co-marketing agreement
The joint work of the two companies will focus on educational and cross-promotional efforts intended to benefit the patients and healthcare professionals served by both companies. The goal
The joint work of the two companies will focus on educational and cross-promotional efforts intended to benefit the patients and healthcare professionals served by both companies. The goal
Based on Durect’s Oradur technology, Remoxy is designed to resist common methods of prescription drug misuse and abuse. Remoxy is being developed by Pain Therapeutics under license from
The agreement grants Mylan exclusive distribution rights in the US and all major markets in Europe, Australia, New Zealand, Japan and Canada and includes an option to expand
Biopure said that the study, HEM-115 that included nearly 700 patients from 46 sites in three continents, is the largest Phase III clinical trial of the safety and
The company recently conducted a review of clinical data from four studies that it had conducted wherein 582 women were treated for autoimmune diseases or fibromyalgia syndrome over
Telintra is currently in Phase II clinical trials for the treatment of myelodysplastic syndrome, a form of pre-leukemia, and for chemotherapy induced neutropenia, a common side effect of
The study, which will consist of two parts and include approximately 70 patients, will be conducted by GlaxoSmithKline. The objective of part A of the study is to
Existing and new investors participated in the financing including Credit Suisse First Boston Next Fund, Crocker Ventures, HNI Holdings, funds advised by Noonday Asset Management, TPG-Axon Capital and
The apixaban after the initial management of pulmonary embolism and deep vein thrombosis with first-line therapy (Amplify) trials are part of the Expanse program – the global Phase
The trial is expected to enroll approximately 200 patients and is designed to confirm the analgesic efficacy of PMI-150 in treating postoperative pain following orthopedic surgery. Prior randomized,